Simvastatin for Treating Erectile Dysfunction (STED)
Primary Purpose
Erectile Dysfunction, Vascular Disease Detected, C Reactive Protein
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Simvastatin
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Erectile Dysfunction focused on measuring simvastatin, endothelial dysfunction, erectile dysfunction
Eligibility Criteria
Inclusion Criteria:
- Erectile dysfunction
- Elevated C reactive protein
- Able to adhere the protocol
Exclusion Criteria:
- Diabetes mellitus
- Cardiac disease
- Cerebral vascular disease
- Hypogonadism
- Any contraindication to simvastatin
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
placebo
Simvastatin
Arm Description
Treatment arm.
Outcomes
Primary Outcome Measures
Penile erection
Secondary Outcome Measures
Full Information
NCT ID
NCT00947323
First Posted
July 27, 2009
Last Updated
September 24, 2010
Sponsor
Santa Casa de Porto Alegre
1. Study Identification
Unique Protocol Identification Number
NCT00947323
Brief Title
Simvastatin for Treating Erectile Dysfunction
Acronym
STED
Official Title
The Effect of Simvastatin in the Penile Erection: a Randomized, Double-blind Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
September 2010
Overall Recruitment Status
Completed
Study Start Date
January 2006 (undefined)
Primary Completion Date
July 2008 (Actual)
Study Completion Date
December 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Santa Casa de Porto Alegre
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a randomized clinical trial, double-blind, placebo controlled, to verify if simvastatin can improve erectile dysfunction in men with endothelial dysfunction, without any cardiac disease.It is hypothesized that the simvastatin can improve the endothelial function, improving the nitric oxide liberation in corpora cavernosa of the penis, resulting in improvement of erection.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Erectile Dysfunction, Vascular Disease Detected, C Reactive Protein
Keywords
simvastatin, endothelial dysfunction, erectile dysfunction
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
Double
Allocation
Randomized
Enrollment
41 (Actual)
8. Arms, Groups, and Interventions
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Title
Simvastatin
Arm Type
Experimental
Arm Description
Treatment arm.
Intervention Type
Drug
Intervention Name(s)
Simvastatin
Intervention Description
simvastatin 20 daily for six months.
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Penile erection
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Erectile dysfunction
Elevated C reactive protein
Able to adhere the protocol
Exclusion Criteria:
Diabetes mellitus
Cardiac disease
Cerebral vascular disease
Hypogonadism
Any contraindication to simvastatin
12. IPD Sharing Statement
Learn more about this trial
Simvastatin for Treating Erectile Dysfunction
We'll reach out to this number within 24 hrs